Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Dec 2;21(1):393.
doi: 10.1186/s12890-021-01770-6.

Serum interleukin-17 predicts severity and prognosis in patients with community acquired pneumonia: a prospective cohort study

Chun-Mei Feng #  1 , Xin-Ming Wang #  2 , Meng-Die Li #  1 , Zheng Xu  1 , Dong-Xu Hua  1 , Jia-Yi Cheng  1 , Ling Zheng  1 , Hui Zhao  3 , Lin Fu  4
Affiliations

Serum interleukin-17 predicts severity and prognosis in patients with community acquired pneumonia: a prospective cohort study

Chun-Mei Feng et al. BMC Pulm Med. .

Abstract

Background: Some studies previously demonstrated that interleukin-17 (IL-17) involves in pulmonary diseases progression. Nevertheless, the role of IL-17 in community-acquired pneumonia (CAP) remains unknown. This study aims to examine the correlations between serum IL-17 with the severity and prognosis in CAP patients through a prospective cohort study.

Methods: All 239 CAP patients were recruited. Serum IL-17 was detected by enzyme-linked immunosorbent assay (ELISA). The CAP severity was evaluated through CAP severity scores, including CURB-65, CRB-65, PSI, SMART-COP, CURXO and APACHE II.

Results: Serum IL-17 was gradually increased consistent with the severity of CAP. Correlative analysis suggested that serum IL-17 was associated with clinical physiologic indicators among CAP patients. Logistic regression indicated that serum IL-17 was positively related to CAP severity scores. Additionally, the prognostic outcomes were tracked among CAP patients. The levels of IL-17 on admission were significantly increased in CAP patients with ICU admission, mechanical ventilation, vasoactive agent, death and longer hospitalization days. Logistic regression analyses revealed serum higher IL-17 on admission elevated the risks of vasoactive agent usage and longer hospital stays in CAP patients. The cut-off concentrations of serum IL-17 for death, ICU admission, mechanical ventilation and ≥ 14 hospital stays were 86.80 ng/mL, 84.92 ng/mL, 84.92 ng/mL and 60.29 ng/mL respectively.

Conclusions: Serum IL-17 on admission is positively associated with the severity and poor prognosis among CAP patients, revealing that IL-17 may implicate in the pathological process of CAP. Therefore, serum IL-17 may become an effective biomarker for diagnosis, prognosis and therapy for CAP patients.

Keywords: Biomarker; CAP severity scores; Community-acquired pneumonia; Interleukin-17; Prognosis.

PubMed Disclaimer

Conflict of interest statement

All authors have declared that no competing interests exists.

Figures

Fig. 1
Fig. 1
The levels of serum IL-17 in CAP patients with different severity scores. A–F The levels of serum IL-17 in CAP patients with different severity scores. A CRB-65 score. B SMART-COP score. C APACHE II score. D CURB-65 score. E CURXO score. F PSI score. All data were expressed as mean ± SEM. *P < 0.05, **P < 0.01
Fig. 2
Fig. 2
The levels of serum IL-17 in CAP patients with different prognostic outcomes. A–E The levels of serum IL-17 in CAP patients with different prognostic outcomes during hospitalizations. A Mechanical ventilation. B Vasoactive agent. C ICU admission. D Lengths of hospital stay. E Death. All data were expressed as mean ± SEM. *P < 0.05, **P < 0.01
Fig. 3
Fig. 3
Receiver operating characteristic curves for prognosis in CAP patients. A ROC curve was used to evaluate the predictive values for death of different biomarkers among CAP patients. B ROC curve was used to evaluate the predictive values for ICU admission of different biomarkers among CAP patients. C ROC curve was used to evaluate the predictive values for mechanical ventilation of different biomarkers among CAP patients. D ROC curve was used to evaluate the predictive values for hospital stays of different biomarkers among CAP patients
See this image and copyright information in PMC

References

    1. Mandell LA, Wunderink RG, Anzueto A. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis. 2007;44(Suppl2):S27–72. doi: 10.1086/511159. - DOI - PMC - PubMed
    1. Menéndez R, Torres A, Zalacaín R, Aspa J, Martín Villasclaras JJ, Borderías L, Benítez Moya JM, Ruiz-Manzano J, Rodríguez de Castro F, Blanquer J, et al. Risk factors of treatment failure in community acquired pneumonia: implications for disease outcome. Thorax. 2004;59(11):960–965. doi: 10.1136/thx.2003.017756. - DOI - PMC - PubMed
    1. Heron M. Deaths: leading causes for 2015. Natl Vital Stat Rep. 2017;66(5):1–76. - PubMed
    1. Broulette J, Yu H, Pyenson B, Iwasaki K, Sato R. The incidence rate and economic burden of community-acquired pneumonia in a working-age population. Am Health Drug Benefits. 2013;6(8):494–503. - PMC - PubMed
    1. File TM, Jr, Marrie TJ. Burden of community-acquired pneumonia in North American adults. Postgrad Med. 2010;122(2):130–141. doi: 10.3810/pgm.2010.03.2130. - DOI - PubMed